Insight Capital Research & Management’s Pacira BioSciences PCRX Stock Holding History

Insight Capital Research & Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-19,540	Closed	-$1.73M	–	137
2014 Q4	$1.73M	Sell	19,540 -59,477	-75%	-$5.63M	0.44%	87
2014 Q3	$7.66M	Sell	79,017 -11,859	-13%	-$1.15M	2%	6
2014 Q2	$8.35M	Sell	90,876 -9,407	-9%	-$716K	1.91%	8
2014 Q1	$7.02M	Buy	100,283 +71,270	+246%	+$4.85M	1.62%	15
2013 Q4	$1.67M	Buy	+29,013	New	+$1.53M	0.37%	91

Other funds holding PCRX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

Marsico Capital Management Denver, Colorado $3.83B AUM 63.68% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Insight Capital Research & Management's PCRX Position: Q1 2015 in Review

Insight Capital Research & Management sold out of Pacira BioSciences (PCRX) in Q1 2015, closing a stake of 19,540 shares — an estimated $1.73M sold.

Insight Capital Research & Management first reported a position in PCRX in Q4 2013 and held it in 5 quarters. The position peaked at $8.35M in Q2 2014. 205 funds tracked by Wall St. Rank hold PCRX as of Q1 2015.

Insight Capital Research & Management reported no remaining Pacira BioSciences position as of Q1 2015 after selling out during the quarter.
Insight Capital Research & Management sold 19,540 Pacira BioSciences shares in Q1 2015, an estimated $1.73M.
Insight Capital Research & Management first reported a position in Pacira BioSciences in Q4 2013 and held it in 5 quarters.
Insight Capital Research & Management's Pacira BioSciences position peaked at $8.35M in Q2 2014.
205 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2015.

Based on Insight Capital Research & Management's 13F filing for Q1 2015, filed 7 May 2015.